Live Breaking News & Updates on Institutional Investors Weigh In On Rhythm Pharmaceuticals

Stay updated with breaking news from Institutional investors weigh in on rhythm pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Up 8.2%

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report)’s stock price rose 8.2% during mid-day trading on Monday . The company traded as high as $39.03 and last traded at $38.61. Approximately 174,823 shares were traded during trading, a decline of 71% from the average daily volume of 604,009 shares. The stock had previously closed at […] ....

United States , New York , Joseph Shulman , Davidp Meeker , Wells Fargo Company , Needham Company , Rhythm Pharmaceuticals Company Profile , Barclays Plc , York State Common Retirement Fund , Institutional Investors Weigh In On Rhythm Pharmaceuticals , Charles Schwab Investment Management Inc , Rhythm Pharmaceuticals , Rhythm Pharmaceuticals Inc , Rhythm Pharmaceuticals Trading , Victory Capital Management Inc , Swiss National Bank , News Ratings For Rhythm Pharmaceuticals Daily , Canaccord Genuity Group , Get Free Report , Genuity Group , Wells Fargo , Capital Management , National Bank , Charles Schwab Investment Management , Schwab Investment Management , Rhythm Pharmaceuticals Daily ,

Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Rating Reaffirmed by Needham & Company LLC

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $50.00 price target on the stock. Needham & Company LLC’s price target would suggest a potential upside […] ....

New Zealand General , New Zealand , Yann Mazabraud , Joseph Shulman , Analyst Recommendations For Rhythm Pharmaceuticals , Needham Company , Wealth Management , Hennion Walsh Asset Management Inc , Rhythm Pharmaceuticals Inc , Virtu Financial , Goldman Sachs Group , Institutional Investors Weigh In On Rhythm Pharmaceuticals , Rhythm Pharmaceuticals Stock Performance , Vanguard Group Inc , Wellington Management Group , Rhythm Pharmaceuticals , Wells Fargo Company , News Ratings For Rhythm Pharmaceuticals Daily , Get Free Report , Walsh Asset Management , Management Group , Rhythm Pharmaceuticals Daily , Nasdaq Rytm , Reiterated Rating , Needham Company Llc ,

Rhythm Pharmaceuticals' (RYTM) "Buy" Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) in a research report released on Friday morning, Benzinga reports. They currently have a $50.00 target price on the stock. A number of other equities analysts also recently commented on RYTM. The Goldman Sachs Group upped their target […] ....

Davidp Meeker , Hunterc Smith , Wells Fargo Company , Silverarc Capital Management , Goldman Sachs Group , Barclays Plc , Victory Capital Management Inc , News Ratings For Rhythm Pharmaceuticals Daily , Rhythm Pharmaceuticals Inc , Rhythm Pharmaceuticals Stock Performance , Analyst Recommendations For Rhythm Pharmaceuticals , Needham Company , Rhythm Pharmaceuticals , Institutional Investors Weigh In On Rhythm Pharmaceuticals , Charles Schwab Investment Management Inc , Free Report , Get Free Report , Capital Management , Capital Partners , Schwab Investment Management , Victory Capital Management , Rhythm Pharmaceuticals Daily , Nasdaq Rytm , Reiterated Rating , Needham Company Llc ,

Rhythm Pharmaceuticals (NASDAQ:RYTM) PT Lowered to $52.00 at Wells Fargo & Company

Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its target price lowered by Wells Fargo & Company from $53.00 to $52.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an overweight rating on the stock. A number of other equities analysts have also recently weighed in on the stock. Needham & Company […] ....

Joseph Shulman , Hunterc Smith , Rhythm Pharmaceuticals Company Profile , Rhythm Pharmaceuticals , Rhythm Pharmaceuticals Stock Performance , Analyst Recommendations For Rhythm Pharmaceuticals , Needham Company , Perceptive Advisors , Blackrock Inc , Goldman Sachs Group , Geode Capital Management , Wells Fargo Company , Securities Exchange Commission , News Ratings For Rhythm Pharmaceuticals Daily , Institutional Investors Weigh In On Rhythm Pharmaceuticals , Rhythm Pharmaceuticals Inc , Hermes Inc , Free Report , Wells Fargo , Get Free Report , Exchange Commission , Street Corp , Capital Management , Rhythm Pharmaceuticals Daily , Nasdaq Rytm , Lower Price Target ,

Christopher Paul German Sells 368 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock

Christopher Paul German Sells 368 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United States , Needham Company , Institutional Investors Weigh In On Rhythm Pharmaceuticals , Rhythm Pharmaceuticals Stock Down , Wells Fargo Company , Securities Exchange Commission , Morgan Stanley , Goldman Sachs Group , Allspring Global Investments Holdings , Rhythm Pharmaceuticals Inc , Rhythm Pharmaceuticals , Quarter For Rhythm Pharmaceuticals , China Universal Asset Management Co , News Ratings For Rhythm Pharmaceuticals Daily , Chicago Partners Investment Group , Get Free Report , Paul German , Exchange Commission , Pharmaceuticals Stock Down , Universal Asset Management , Partners Investment Group , Global Investments Holdings , Rhythm Pharmaceuticals Daily ,